WO1996041606A3 - Compositions pharmaceutiques ameliorees utilisees pour la therapie genique - Google Patents
Compositions pharmaceutiques ameliorees utilisees pour la therapie genique Download PDFInfo
- Publication number
- WO1996041606A3 WO1996041606A3 PCT/GB1996/001396 GB9601396W WO9641606A3 WO 1996041606 A3 WO1996041606 A3 WO 1996041606A3 GB 9601396 W GB9601396 W GB 9601396W WO 9641606 A3 WO9641606 A3 WO 9641606A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- pharmaceutical compositions
- gene therapy
- improved pharmaceutical
- peptides
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96917590A EP0831922A2 (fr) | 1995-06-08 | 1996-06-10 | Compositions pharmaceutiques ameliorees utilisees pour la therapie genique |
AU60114/96A AU6011496A (en) | 1995-06-08 | 1996-06-10 | Improved pharmaceutical compositions for gene therapy |
JP50279197A JP2002514892A (ja) | 1995-06-08 | 1996-06-10 | 遺伝子治療における合成ウイルス様粒子の使用 |
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12495P | 1995-06-08 | 1995-06-08 | |
GB9513399.7 | 1995-06-30 | ||
GBGB9513399.7A GB9513399D0 (en) | 1995-06-30 | 1995-06-30 | Improved pharmaceutical compositions for gene therapy |
GBGB9519304.1A GB9519304D0 (en) | 1995-09-21 | 1995-09-21 | Improved pharmaceutical compositions for gene therapy |
GB9519304.1 | 1995-09-21 | ||
US428595P | 1995-09-25 | 1995-09-25 | |
US895295P | 1995-12-19 | 1995-12-19 | |
GBGB9525955.2A GB9525955D0 (en) | 1995-12-19 | 1995-12-19 | Improved pharmaceutical compositions |
US1153196P | 1996-02-12 | 1996-02-12 | |
US66023196A | 1996-06-07 | 1996-06-07 | |
US60/004,285 | 1996-06-07 | ||
US08/660,231 | 1996-06-07 | ||
US60/011,531 | 1996-06-07 | ||
US60/000,124 | 1996-06-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US86128397A Continuation-In-Part | 1996-02-12 | 1997-05-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996041606A2 WO1996041606A2 (fr) | 1996-12-27 |
WO1996041606A3 true WO1996041606A3 (fr) | 1997-05-22 |
Family
ID=27571323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/001396 WO1996041606A2 (fr) | 1995-06-08 | 1996-06-10 | Compositions pharmaceutiques ameliorees utilisees pour la therapie genique |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0831922A2 (fr) |
JP (1) | JP2002514892A (fr) |
AU (1) | AU6011496A (fr) |
WO (1) | WO1996041606A2 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479464B1 (en) | 1997-05-21 | 2002-11-12 | Cobra Therapeutics Limited | Compositions and methods for highly efficient transfection |
WO1997028818A1 (fr) * | 1996-02-12 | 1997-08-14 | Cobra Therapeutics Limited | Nouveaux procedes de vaccination et vaccins associes comprenant un acide nucleique codant un premier epitope, ainsi qu'un peptide contenant un second epitope |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
US8007784B1 (en) | 1996-06-27 | 2011-08-30 | Albany Medical College | Antigenic modulation of cells |
DE69836746D1 (de) * | 1997-02-12 | 2007-02-08 | Innovata Plc Nottingham | Zusammensetzungen sowie verfahren zur hocheffizienten transfektion |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5912239A (en) * | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948925A (en) * | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5952516A (en) * | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
AU7987898A (en) * | 1997-06-26 | 1999-01-19 | Albany Medical College | Antigenic modulation of viral particules |
WO1999040771A2 (fr) | 1998-02-13 | 1999-08-19 | Selective Genetics, Inc. | Procedes de melange de flux en parallele, appareils de preparation de vecteurs pour la therapie genique et compositions preparees de cette maniere |
WO1999042091A2 (fr) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Compositions d'apport dans des cellules |
CA2333852C (fr) | 1998-07-21 | 2007-05-29 | Cobra Therapeutics Limited | Polynucleotide comportant un element d'ouverture de la chromatine ubiquiste (ucoe) |
AU5590999A (en) * | 1998-09-01 | 2000-03-21 | Trustees Of The University Of Pennsylvania, The | Peptide scaffolds for transfer of molecules into eukaryotic cells |
US6927278B1 (en) | 1998-09-01 | 2005-08-09 | Trustees Of The University Of Pennsylvania | Peptide scaffolds for transfer of molecules into eukaryotic cells |
WO2000063409A1 (fr) * | 1999-04-21 | 2000-10-26 | Massachusetts Institute Of Technology | Agents endosomolytiques et systemes de liberation dans des cellules |
WO2000075162A1 (fr) * | 1999-06-07 | 2000-12-14 | Mirus Corporation | Compose contenant une liaison instable de bisulfure |
WO2000075164A1 (fr) * | 1999-06-07 | 2000-12-14 | Mirus Corporation | Compositions et methodes de diffusion de medicaments au moyen de molecules sensibles au ph |
GB9918670D0 (en) | 1999-08-06 | 1999-10-13 | Celltech Therapeutics Ltd | Biological product |
JP2004500097A (ja) | 2000-03-02 | 2004-01-08 | エムエル ラボラトリーズ ピーエルシー | Tcf応答性エレメント |
EP1272221A2 (fr) * | 2000-04-12 | 2003-01-08 | Implyx Ltd. | Conjugues de peptides utilises pour l'apport de medicament |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
JP5102630B2 (ja) * | 2005-11-24 | 2012-12-19 | ジェノミディア株式会社 | 改変パラミクソウイルスおよびその作製方法 |
CA2740685C (fr) | 2008-10-17 | 2018-09-11 | Sanofi-Aventis Deutschland Gmbh | Combinaison d'une insuline et d'un agoniste de glp-1 |
JP5973918B2 (ja) | 2009-11-13 | 2016-08-23 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Glp−1アゴニスト及びメチオニンを含む薬学的組成物 |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
EP3689381A1 (fr) | 2010-06-22 | 2020-08-05 | Onxeo | Système d'administration in vivo optimisé doté d'agents endosomolytiques pour conjugués d'acides nucléiques |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
HRP20230470T1 (hr) | 2014-12-12 | 2023-07-21 | Sanofi-Aventis Deutschland Gmbh | Formulacija fiksnog omjera inzulin glargin/liksisenatid |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
JP6661797B2 (ja) * | 2016-11-22 | 2020-03-11 | 株式会社東芝 | 核酸凝縮ペプチド、核酸凝縮ペプチドセット、核酸送達キャリア、核酸送達方法、細胞作製方法、細胞検出方法及びキット |
AU2018286475A1 (en) | 2017-06-13 | 2019-12-19 | Monash University | Non-viral gene delivery agent comprising lipopeptide (LP) compounds |
MX2021005313A (es) * | 2018-11-08 | 2021-10-13 | Summation Bio Inc | Proteínas de núcleo de mininucleosoma y uso en entrega de ácido nucleico. |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0544292A2 (fr) * | 1991-11-27 | 1993-06-02 | Roche Diagnostics GmbH | Méthode d'introduction d'acides nucléiques dans des cellules |
WO1993019768A1 (fr) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Systeme de livraison d'un polynucleotide a assemblage autonome |
DE4412629A1 (de) * | 1993-04-14 | 1995-01-26 | Boehringer Mannheim Gmbh | Nukleinsäure-transferpeptide und deren Verwendung zur Einschleusung von Nukleinsäuren in eukaryontische Zellen |
WO1995006056A1 (fr) * | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Conjugues polycationiques polymeres-oligonucleotides a pont et procedes de preparation |
WO1995021931A1 (fr) * | 1994-02-08 | 1995-08-17 | Rhone-Poulenc Rorer S.A. | Composition contenant des acides nucleiques, preparation et utilisations |
WO1996019241A1 (fr) * | 1994-12-19 | 1996-06-27 | Medical Research Council | Complexes de ciblage et leur utilisation |
WO1996025508A1 (fr) * | 1995-02-17 | 1996-08-22 | Rhone-Poulenc Rorer S.A. | Compositions contenant des acides nucleiques, preparation et utilisation |
-
1996
- 1996-06-10 EP EP96917590A patent/EP0831922A2/fr not_active Withdrawn
- 1996-06-10 JP JP50279197A patent/JP2002514892A/ja active Pending
- 1996-06-10 AU AU60114/96A patent/AU6011496A/en not_active Abandoned
- 1996-06-10 WO PCT/GB1996/001396 patent/WO1996041606A2/fr not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0544292A2 (fr) * | 1991-11-27 | 1993-06-02 | Roche Diagnostics GmbH | Méthode d'introduction d'acides nucléiques dans des cellules |
WO1993019768A1 (fr) * | 1992-04-03 | 1993-10-14 | The Regents Of The University Of California | Systeme de livraison d'un polynucleotide a assemblage autonome |
DE4412629A1 (de) * | 1993-04-14 | 1995-01-26 | Boehringer Mannheim Gmbh | Nukleinsäure-transferpeptide und deren Verwendung zur Einschleusung von Nukleinsäuren in eukaryontische Zellen |
WO1995006056A1 (fr) * | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Conjugues polycationiques polymeres-oligonucleotides a pont et procedes de preparation |
WO1995021931A1 (fr) * | 1994-02-08 | 1995-08-17 | Rhone-Poulenc Rorer S.A. | Composition contenant des acides nucleiques, preparation et utilisations |
WO1996019241A1 (fr) * | 1994-12-19 | 1996-06-27 | Medical Research Council | Complexes de ciblage et leur utilisation |
WO1996025508A1 (fr) * | 1995-02-17 | 1996-08-22 | Rhone-Poulenc Rorer S.A. | Compositions contenant des acides nucleiques, preparation et utilisation |
Non-Patent Citations (2)
Title |
---|
LEGENDRE, J.-Y. ET AL.: "Cyclic amphipathic peptide-DNA complexes mediate high-efficiency transfection of adherent mammalian cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, February 1993 (1993-02-01), WASHINGTON US, pages 893 - 897, XP002023679 * |
ROKEACH LA ET AL: "Molecular cloning of a cDNA encoding the human Sm-D autoantigen.", PROC NATL ACAD SCI U S A, JUL 1988, VOL. 85, NO. 13, PAGE(S) 4832-6, XP002023680 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9408893B2 (en) | 2011-08-29 | 2016-08-09 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
US9364519B2 (en) | 2011-09-01 | 2016-06-14 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
Also Published As
Publication number | Publication date |
---|---|
EP0831922A2 (fr) | 1998-04-01 |
WO1996041606A2 (fr) | 1996-12-27 |
JP2002514892A (ja) | 2002-05-21 |
AU6011496A (en) | 1997-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996041606A3 (fr) | Compositions pharmaceutiques ameliorees utilisees pour la therapie genique | |
Arar et al. | Synthesis and Antiviral Activity of Peptide-Oligonucleotide Conjugates Prepared by Using N. Alpha.-(Bromoacetyl) Peptides | |
CA2370289A1 (fr) | Peptides inhibiteurs de l'exocytose neuronale, compositions cosmetiques et pharmaceutiques les contenant | |
WO2000003683A3 (fr) | Complexes d'acides nucleiques encapsules dans des liposomes | |
IL112372A (en) | Non-viral vector for the delivery of genetic information to cells | |
EP1188768A3 (fr) | Peptides antagonistes de LHRH | |
AU4526193A (en) | Binding competent oligomers containing 2', 5' linkages | |
AU2790292A (en) | Viral recombinant vectors for expression in muscle cells | |
ATE238038T1 (de) | Liposomale formulierungen von mitoxantron | |
CA2257133A1 (fr) | Variantes hyperactives de la desoxyribonuclease i humaine | |
CA2333145A1 (fr) | Dispositif de liberation de medicaments comprenant un peptide a homeoboite et un composant de liberation de nature non peptidique et non nucleotidique | |
NZ289899A (en) | Peptide which binds to the p53 suppressor site of the MDM2 oncogene | |
WO2003068144A3 (fr) | Agents cytotoxiques supportant une fraction reactive de polyethyleneglycol, conjugues cytotoxiques comprenant des groupes de liaison de polyethyleneglycol et leurs procedes de fabrication et d'utilisation | |
CA2242035A1 (fr) | Compositions utiles pour le transfert de substances therapeutiques actives dans une cellule-cible, et leur utilisation en therapie genique | |
WO2002064766A3 (fr) | Genes reagissant a bax, destines a l'identification des cibles de medicaments dans la levure et les champignons | |
EP0349342A3 (fr) | Polypeptides ayant une activité dispersante de cellules | |
GB9722320D0 (en) | Human cell cycle checkpoint proteins | |
ATE215099T1 (de) | Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie | |
NZ331063A (en) | Isolated nucleotide sequences encoding for mature LS- DNase which is resistant to actin inhibition | |
CA2155017A1 (fr) | Fonction proteinique vpr et activite de celle-ci | |
NZ504445A (en) | Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive | |
ATE391186T1 (de) | Gezielte verabreichung von kuenstlichen genen | |
EP1020529A3 (fr) | Vecteurs d'apport de gènes munis d'un tropisme pour les cellules des muscles lisses et/ou les cellules endothéliales | |
WO2001057069A3 (fr) | Peptides capables de ciblage | |
PT1294874E (pt) | Variantes de cd154 e as suas utilizacoes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Free format text: GB US |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2224146 Country of ref document: CA Ref country code: CA Ref document number: 2224146 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996917590 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996917590 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996917590 Country of ref document: EP |